WORCESTER, Mass., July 17, 2007 (PRIME NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced today that it will be participating in the Diet, Nutrition & Vitamin Efficient Program Planning Session (EPPS) held in Jacksonville, FL July 16 - 19, 2007 (www.ecrm-epps.com). The session will be held at the Hyatt Regency Jacksonville Riverfront.
The company will be introducing three products from their Consumer Healthcare Product Marketing and Distribution Division to buyers at the planning session: Glucose RapidSpray (www.GlucoseRapidSpray.com), GlucoBreak (www.GlucoBreak.com) and BaBoom! Energy Spray (www.BaBoomEnergySpray.com).
The EPPS category-specific events consist of one-on-one planning sessions scheduled between Suppliers and Buyers to review new items, promotions, marketing initiatives and strategic direction. The one-on-one planning sessions average about 20 minutes and can replace the sales presentation in the Buyer's office saving both Suppliers and Buyers time and money. The focus of the EPPS Diet, Nutrition & Vitamin Event will be on the presentation and review of new products, marketing initiatives and promotional opportunities in the following categories: Vitamin, Diet, Nutrition and Adult Nutrition.
"This event provides the Company with an effective marketing tool to introduce the Company's RapidSpray platform products to an audience of buyers who serve as decision makers for retail space," says Rose C. Perri, Generex's Chief Operating Officer. "It is also a cost-effective means of marketing as the Company rolls out each product from its Consumer Healthcare Product Marketing and Distribution division."
About Generex
Generex is engaged in the research and development of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist device. The Company's flagship product, oral insulin (Generex Oral-lyn), which is available for sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes, and before the end of 2007 the Company expects to begin Phase 3 trials of the product in the United States, Canada and Europe. For more information, visit the Generex website at www.generex.com.
Safe Harbor Statement: This release and oral statements made from time to time by Generex representatives concerning the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.